文献速递MDS 与骨髓增殖性肿瘤白血病

阿扎胞苷单药或联合来那度胺或伏立诺他治疗高危骨髓增生异常综合征和慢性粒单核细胞白血病的随机II期研究:北美协作组SWOG S1117

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
PubMed 文献 · J Clin Oncol · 2017-05-09

北美协作组S1117研究将277例高危骨髓增生异常综合征和慢性粒单核细胞白血病患者按1:1:1随机分配至阿扎胞苷单药、阿扎胞苷联合来那度胺或阿扎胞苷联合伏立诺他组,主要II期终点为总缓解率(ORR)。联合组ORR与单药组相似,但慢性粒单核细胞白血病患者接受阿扎胞苷联合来那度胺的ORR高于单药组(68% vs 28%,P=0.02)。

要点

  • 阿扎胞苷联合来那度胺或伏立诺他组ORR与阿扎胞苷单药组无显著差异。
  • 慢性粒单核细胞白血病患者接受阿扎胞苷联合来那度胺的ORR高于阿扎胞苷单药(68% vs 28%,P=0.02)。
  • 来那度胺剂量降低与更差的总生存相关(风险比1.30,P=0.05)。

核心结论

  • 高危骨髓增生异常综合征患者接受阿扎胞苷为基础的联合方案与阿扎胞苷单药治疗的ORR相似,但慢性粒单核细胞白血病患者从阿扎胞苷联合来那度胺中获益。
  • 联合方案的疗效可能受到剂量调整的影响。

研究设计与样本

  • 北美协作组S1117研究是一项II/III期随机试验,将高危骨髓增生异常综合征和慢性粒单核细胞白血病患者按1:1:1随机分配至阿扎胞苷单药组、阿扎胞苷联合来那度胺组或阿扎胞苷联合伏立诺他组。
  • 阿扎胞苷剂量为75 mg/m2/天,28天周期中第1至7天给药;来那度胺10 mg/天,第1至21天给药;伏立诺他300 mg每日两次,第3至9天给药。
  • 来自90个中心的277例患者纳入分析,其中92例接受阿扎胞苷单药,93例接受阿扎胞苷联合来那度胺,92例接受阿扎胞苷联合伏立诺他。
  • 中位年龄70岁(范围28至93岁),85例(31%)为女性,53例(19%)患有慢性粒单核细胞白血病。
  • 主要II期终点为总缓解率(ORR)改善。

主要发现

  • 中位随访23个月(范围1至43个月),阿扎胞苷单药组ORR为38%,阿扎胞苷联合来那度胺组为49%(vs 阿扎胞苷单药P=0.14),阿扎胞苷联合伏立诺他组为27%(vs 阿扎胞苷单药P=0.16)。
  • 慢性粒单核细胞白血病患者中,阿扎胞苷联合来那度胺组ORR高于阿扎胞苷单药组(68% vs 28%,P=0.02)。
  • 各细胞遗传学亚组间ORR相似,缓解持续时间和总生存也相似。
  • DNMT3A突变者ORR较高,SRSF2突变者ORR较低;突变数目较少者ORR持续时间改善。
  • 来那度胺剂量降低与更差的总生存相关(风险比1.30,P=0.05)。

关键数值与推荐

  • 阿扎胞苷单药组ORR为38%,阿扎胞苷联合来那度胺组为49%(vs 阿扎胞苷单药P=0.14),阿扎胞苷联合伏立诺他组为27%(vs 阿扎胞苷单药P=0.16)。
  • 慢性粒单核细胞白血病患者中,阿扎胞苷联合来那度胺组ORR为68%,阿扎胞苷单药组为28%(P=0.02)。
  • 来那度胺剂量降低与更差的总生存相关(风险比1.30,P=0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Azacitidine is standard, first-line therapy in higher-risk myelodysplastic syndromes (MDS). Whether azacitidine-based combinations with lenalidomide or vorinostat produce superior overall response rates (ORRs) to azacitidine is not known. Patients and Methods North American Intergroup Study S1117 is a phase II/III trial that randomly assigned patients with higher-risk MDS and chronic myelomonocytic leukemia (CMML) 1:1:1 to azacitidine (75 mg/m2/day on days 1 to 7 of a 28-day cycle); azacitidine plus lenalidomide (10 mg/day on days 1 to 21); or azacitidine plus vorinostat (300 mg twice daily on days 3 to 9). The primary phase II end point was improved ORR. Results Of 277 patients from 90 centers, 92 received azacitidine, 93 received azacitidine plus lenalidomide, and 92 received azacitidine plus vorinostat. Median age was 70 years (range, 28 to 93 years), 85 patients (31%) were female, and 53 patients (19%) had CMML. Serious adverse events were similar across arms, although combination-arm patients were more likely to undergo nonprotocol-defined dose modifications ( P < .001).With a median follow-up of 23 months (range, 1 to 43 months), the ORR was 38% for patients receiving azacitidine, 49% for azacitidine plus lenalidomide ( P = .14 v azacitidine), and 27% for azacitidine plus vorinostat ( P = .16 v azacitidine). For patients with CMML, ORR was higher for azacitidine plus lenalidomide versus azacitidine (68% v 28%, P = .02) but similar for all arms across cytogenetic subgroups, as was remission duration and overall survival. ORR was higher with mutations in DNMT3A and lower for SRSF2, whereas ORR duration improved with fewer mutations. Lenalidomide dose reduction was associated with worse overall survival (hazard ratio, 1.30; P = .05). Conclusion Patients with higher-risk MDS treated with azacitidine-based combinations had similar ORR to azacitidine monotherapy, although patients with CMML benefitted from azacitidine plus lenalidomide. The efficacy of combination regimens may have been affected by dose modifications.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sekeres MA, Othus M, List AF, et al. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017. PMID: 28486043. doi:10.1200/JCO.2015.66.2510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。